HOME >> BIOLOGY >> NEWS
New drugs for bad bugs

GAINESVILLE, Fla. -- Call it a chemical crystal ball. A new approach to predict whether a drug in development is likely to work and which dose is best could get antibiotics to market faster and more cheaply, say University of Florida researchers.

In recent years, scientists worldwide have sounded the alarm: There simply aren't enough drugs to combat bad bugs. Bacteria are increasingly adept at outwitting the traditional antibiotic arsenal.

Yet designing and testing new antibiotics can be a maddeningly slow and costly process -- if pharmaceutical companies even bother, says Hartmut Derendorf, chairman of the department of pharmaceutics at the University of Florida College of Pharmacy. Many would rather invest in compounds aimed at patients with chronic conditions such as high cholesterol or diabetes, not in drugs designed to be used for a week or two and then stopped once an infection clears, he said.

Now UF researchers have devised a patent-pending method that combines testing of various drug concentrations at the site of infection with a series of laboratory analyses and mathematical models designed to streamline drug development.

The method helps better determine which drugs are worth studying in people and at which dose, avoiding the typically lengthy and expensive trial-and-error approach that can take years.

"About one new antibiotic a year is approved," said Derendorf, who will discuss the technique Saturday (March 5) at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics in Orlando. "That's certainly not enough. Even more worrisome, there are very few in the pipeline right now. Meanwhile, the requirements are getting longer and longer, and this is a huge dilemma with the recent discussion about Vioxx. That's created some doubt in the approval procedure. I think we have to come to a reasonable expectation here in terms of the balance between benefits and potential harm. The worries I
'"/>

Contact: Melanie Ross
ufcardiac@aol.com
352-392-2624
University of Florida
4-Mar-2005


Page: 1 2 3 4

Related biology news :

1. MIT model could predict cells response to drugs
2. New target for HIV/AIDS drugs and vaccine discovered
3. Modified mushrooms may yield human drugs
4. UGR researchers design an alternative to blood test to detect drugs in the body
5. Could fungal collection hold the key to new life-saving drugs?
6. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
7. Scientists develop new drugs to fight colon and breast cancer more effectively
8. Anti-inflammatory drugs interact with HRT, and more
9. Generic biologic drugs unlikely to offer significant savings
10. Stem cells provide new tool for studying disease and identifying ALS drugs
11. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drugs for bad bugs

(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
(Date:6/17/2015)... , June 17, 2015 QIAGEN ... launched new Investigator ® STR assay kits for analysis ... United States . The new genetic fingerprint kits provide ... (short tandem repeats or STRs) for DNA matching. They incorporate ... of DNA in each sample, a novel QIAGEN technology that ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
(Date:7/2/2015)... PALO ALTO, Calif. (PRWEB) , ... July 02, 2015 , ... ... designed to improve an individual’s quality of sleep, launched its Indiegogo campaign on June ... and functionality: Luzi's voice command technology makes it effortless to use, while the integration ...
(Date:7/1/2015)... , ... July 01, 2015 , ... It is now ... (TBI) using single photon emission computed tomography (SPECT) according to researchers from ... which examined over 20,000 brain scans and is believed to be the largest brain ...
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
(Date:7/1/2015)... and BANGALORE, India , July 1, ... company that uses next generation sequencing technology to empower ... A. Storrer as chief executive officer. In his ... be responsible for all strategy, business expansion and worldwide ... has served as Strand,s chairman and CEO since its ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
Cached News: